About Armata Pharmaceuticals Inc
- Industry: Biotechnology
- Exchange: NYSE MKT LLC
- Country: US
- Website: https://www.armatapharma.com/
Frequently Asked Questions
What is the 52-week range for ARMP?
The 52-week high is $16.34 and the 52-week low is $2.94.
What is the P/E ratio for ARMP?
The P/E ratio data is currently unavailable.
What is the dividend yield for ARMP?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -120.00%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -3467.04%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 1.24.
Analyst Recommendation Trends
Wall Street analyst consensus for ARMP over the last few months:
Latest ARMP News
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers GlucoTrack (NASDAQ:GCTK) stock moved upwards by 90.6% to $3.87 during Wednesday's after-market session. The market value of their outstanding shares is at $1.7 million. Greenland Mines (NASDAQ:GRML) shares
Armata Pharmaceuticals Stock Slides after Pentagon Funding Fuels Phase 3 Push for Anti-Bacterial Program
Armata Pharmaceuticals technical headwinds overshadow a $3.7 million Department of Defense grant funding its Phase 3 bacteriophage program.
Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity and potency, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has received an additional $3.7 million in non-dilutive funds from the U.S. Department of War ("DoW") to support activities associated with the Phase 3 development p
HC Wainwright & Co. Reiterates Buy on Armata Pharmaceuticals, Maintains $15 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Armata Pharmaceuticals (AMEX:ARMP) with a Buy and maintains $15 price target.
Armata Pharmaceuticals Receives Additional $3.7M In Non-dilutive Funds From US Department Of War For Phase 3 Development Program For AP-SA02
Importantly, the $3.7 million represents the first funding received specifically for Phase 3 execution pursuant to a previously announced DoW award, received through the Medical Technology Enterprise Consortium
Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity and potency, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced it will present data showing that defined, controlled genetic diversity within AP-SA02 may enhance the product's ability to kill certain Staphylococcus aureus ("S. aureus")
What's going on in today's after hours session
After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Circle8 Group (NASDAQ:CIRC) stock moved upwards by 14.6% to $0.57 during Monday's after-market session. The company's market cap stands at $50.2 million. Eocene (NASDAQ:EOCN) shares rose 10.65% to
The market is filled with gapping stocks in Monday's session.
The session on Monday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
Armata Pharmaceuticals Shares Rise 8% After FDA Grants AP-SA02 Breakthrough Therapy Designation
Armata Pharmaceuticals (AMEX:ARMP) shares rose 8% after the company said the US Food and Drug Administration granted Breakthrough Therapy designation to AP-SA02, its intravenously administered Staphylococcus aureus multi-phage product candidate. The designation covers AP-SA02 as an adjunct treatment for complicated bacteremia caused by methicillin-sensitive S.
Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity and potency, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the U.S. Food and Drug Administration (the "FDA") has granted Breakthrough Therapy designation to AP-SA02, the Company's intravenously administered Staphylococcus aureu
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) stock moved upwards by 44.6% to $2.4 during Monday's pre-market session. The company's market cap stands at $1.1 million. Definium Therapeutics (NASDAQ:DFTX)
Armata Pharmaceuticals Receives FDA Breakthrough Therapy Designation For Its Intravenously Administered Staphylococcus Aureus Multi-Phage Product Candidate AP-SA02
Designation for adjunct treatment of complicated bacteremia caused by methicillin-sensitive S. aureus ("MSSA") or methicillin-resistant S. aureus ("MRSA"). Breakthrough Therapy designation is intended to
Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Deborah Birx, M.D., Chief Executive Officer, will participate in a corporate presentation at the H.C. Wainwright 28th Annual Global Investment Conference, which is being held in Ne
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-07-10 | Birx Deborah | -14,041 | $4.26 | $59,815 |
| 2026-04-24 | Gilmer Daniel B. | +51,280 | - | - |
| 2026-03-14 | Kyme Pierre | -1,030 | $10.54 | $10,856 |
| 2026-03-14 | Birx Deborah | -4,919 | $10.54 | $51,846 |
| 2026-03-09 | House David Duane | +109,885 | - | - |
| 2026-03-09 | Kyme Pierre | +183,142 | - | - |
| 2026-03-09 | Birx Deborah | +421,226 | - | - |
| 2026-03-09 | Peterson Todd C. | +25,640 | - | - |
| 2026-03-09 | Kramer Robin | +25,640 | - | - |
| 2026-03-09 | Schlesinger Sarah J. | +25,640 | - | - |
| 2026-03-09 | Odysseas Kostas D | +25,640 | - | - |
| 2026-03-09 | Haimovitz Jules | +25,640 | - | - |
| 2026-03-09 | PATTI JOSEPH M | +25,640 | - | - |